Advertising Disclosure Email Disclosure

Legal Updates for Toxic Torts Litigation

May 18, 2018
Presented by the Asbestos and Mass Tort Litigation Practice Group

Edited by Timothy D. Rau, Esq.

Aplastic Anemia Not Caused by Benzene Exposure, Philly Jury Says

After a two-and-one-half week trial before Judge Theresa Carpenter, a Philadelphia jury concluded that plaintiff's Aplastic Anemia (AA) was not caused by the benzene exposure, which allegedly resulted from use of the defendants' products. In the case of Estate of John Simmons v. U.S. Steel, Phila CCP, August Term 2015, No. 4219, it was alleged that Mr. Simmons developed AA at the age of 62 as a result of exposure to benzene components in products he used while working in various capacities and in non-occupational automotive repair. Mr. Simmons died two-and-one-half years after his diagnosis at the age of 65, and the action was pursued by Mr. Simmons’ wife.

At trial, plaintiff was represented by Andrew DuPont of Locks Law who relied on expert testimony from Dr. Richard Shadduck, a hematologist, Dr. Peter Infante, an occupational medicine specialist, and Andrew Armstrong, a chemical forensics expert. Plaintiff argued that the defendants' products were defective because they contained components that were comprised, in part, of benzene and that the defendants failed to warn about the hazards associated with the products.

The defendants remaining at verdict were US Steel and Berryman, who allegedly had liability for solvents that were used by Mr. Simmons. The defendants relied on experts Dr. David Pyatt, a toxicologist, Dr. Ethan Natelson and John Spencer, a certified industrial hygienist. The defendants argued that Mr. Simmons' AA was not caused by benzene exposure but was related to other risk factors, such as his 40- to 60-pack per year smoking history.

The jury deliberated for several hours and concluded that the defendants' products were not a factual cause of Mr. Simmons' disease.

 

U.S. Supreme Court to Review Bare Metal Defense

On May 14, 2015, the US Supreme Court granted Certiorari to review the consolidated cases of In RE: Asbestos Litigation (No. VI) DeVries and McAfee, No. 16-2602 (McAfee) to determine the applicability of the bare metal defense under maritime law. As reported in the fall, the Third Circuit issued an opinion in these cases holding that there was no bright-line test for determining if a company could be liable for others' components parts used on the defendants' equipment.

Rather, the court held that a determination needed to be made to determine if a defendant reasonably could have known the following when it placed the product into the stream of commerce:

1)         asbestos is hazardous, and

2)         its product will be used with an asbestos-containing part, because

a)         the product was originally equipped with an asbestos- containing part...

b)         the manufacturer specifically directed that the product be used with an asbestos-containing part, or

c)         the product required an asbestos-containing part to function properly.

The court will issue a schedule for submission of briefs and schedule oral argument during the current term.

 

PA Bill Seeks to Restore Workers’ Compensation as the Exclusive Remedy Against Employers

Until 2013, Pennsylvania's Workers’ Compensation Act (Act) operated to provide workers’ compensation remedies to persons injured at work, and the Act operates as the exclusive source of recovery for persons seeking compensation from their employers for injuries that occur at work. Since the Pennsylvania Supreme Court's landmark opinion in Tooey v. AP Green, 81 A.3d 851 (Pa. 2013), Pennsylvania employers have been named as defendants in lawsuits in which they had previously been precluded from being and have increasingly become target defendants in those lawsuits.

Under the Act, claims for injuries occurring during the course of employment must be filed within 300 weeks of the date of injuries, or in the case of latent diseases, the diagnosis must occur within 300 weeks of the employee's last date of employment. Under the Act as currently written, if a latent disease is not diagnosed within 300 weeks from the employee's last date of employment, the employee's claim under the Act is time-barred.

The Tooey court ruled that because the plaintiff's claims were time barred against the employer under the Act, there was no remedy and the exclusivity that had previously barred plaintiffs from filing suit against employers in areas such as asbestos litigation no longer applied. As a result, employers in latent disease cases, such as asbestos cases, are now being named as defendants.

House Bill No. 2207 seeks to amend the language in the Act to allow a person diagnosed with an occupational disease time to file a claim related to the disease within 300 weeks after the disease is diagnosed or "the disease is detectable." It will be the burden of the claimant to prove that the latency period for the disease claimed is more than the 300 weeks typically allowed as the time period for filing claims.

The effect of the proposed change in the language would be that any persons alleging that they developed a disease as a result of their work would be limited to recovery against the allegedly responsible employers to recovery of those benefits available under the Act. The Bill has been referred to the committee for Labor and Industry, which can hold hearings on the Bill and consider whether to recommend it for a vote.

 

The material in this law alert has been prepared for our readers by Marshall Dennehey Warner Coleman & Goggin. It is solely intended to provide information on recent legal developments, and is not intended to provide legal advice for a specific situation or to create an attorney-client relationship.

We welcome the opportunity to provide such legal assistance as you require on this and other subjects. To be removed from our list of subscribers who receive these complimentary Legal Updates for Toxic Torts Litigation, please contact tdrau@mdwcg.com. If however you continue to receive the alerts in error, please send a note to tdrau@mdwcg.com.

ATTORNEY ADVERTISING pursuant to New York RPC 7.1      © 2018 Marshall Dennehey Warner Coleman & Goggin. All Rights Reserved.

 

Affiliated Attorney

Timothy D. Rau
Shareholder
(215) 575-2623
tdrau@mdwcg.com

Practice Areas

Before you send this email please note:

You are attempting to send email, through a link on our website, to an attorney of Marshall Dennehey Warner Coleman & Goggin or an employee in our firm. Please note that your email may not be treated as confidential and does not create an attorney-client relationship. You should not rely upon the transmission of an email through this website if you are seeking to enter into such a relationship. Until such time as we have agreed to represent you, no information in your email will be treated as confidential. Please contact us directly by telephone at 1.800.220.3308 if it is your intent to seek legal counsel with our firm or convey confidential information.

If it is still your intent to send this email, knowing that it may not be treated as confidential, you may accept our terms of agreement by pressing "OK". If you choose not to accept these terms of agreement you may navigate away from this page by pressing "Cancel."